Halozyme Therapeutics (HALO) Tops Q1 EPS by 8c
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $110.19 -0.51%
Revenue Growth %: +36.2%
Financial Fact:
Revenues under collaborative agreements: 5.49M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +36.2%
Financial Fact:
Revenues under collaborative agreements: 5.49M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q1 EPS of $0.47, $0.08 better than the analyst estimate of $0.39. Revenue for the quarter came in at $162.14 million versus the consensus estimate of $180.51 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- Bernstein SocGen Group Reiterates Outperform Rating on Zydus Lifesciences (ZYDUSLIF:IN)
- JPMorgan Starts Bytes Technology Group PLC (BYIT:LN) at Underweight
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
